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Abstract      1 
Pomegranate extract was tested for its ability to inhibit α-amylase and α-glucosidase activity. 2 
Pomegranate extract strongly inhibited rat intestinal α-glucosidase in vitro whereas it was a 3 
weak inhibitor of porcine α-amylase. The inhibitory activity was recovered in an 4 
ellagitannins-enriched fraction and punicalagin, punicalin and ellagic acid were identified as 5 
α-glucosidase inhibitors (IC50 of 140.2, 191.4 and 380.9 μmol/L, respectively). Kinetic 6 
analysis suggested that the pomegranate extract and ellagitannins inhibited α-glucosidase 7 
activity in a mixed mode. The inhibitory activity was demonstrated using an in vitro digestion 8 
system, mimicking the physiological gastro-intestinal condition, and potatoes as food rich in 9 
starch. Pre-incubation between ellagitannins and α-glucosidase increased the inhibitory 10 
activity, suggesting that they acted by binding to α-glucosidase. During digestion punicalin 11 
and punicalagin concentration decreased. Despite this loss, the pomegranate extract retained 12 
high inhibitory activity. This study suggests that pomegranate ellagitannins may inhibit α-13 
glucosidase activity in vitro possibly affecting in vivo starch digestion. 14 
 15 
Keywords: pomegranate, ellagitannins, starch digestion, diabetes, mass spectrometry16 




High intakes of fruit and vegetables have been associated with a lower incidence of chronic 19 
diseases including diabetes, cardiovascular diseases and cancer (Boeing et al. 2012). It is now 20 
widely accepted that the protection supplied by fruit and vegetables against diseases is due to 21 
the presence of various bioactive compounds. Phenolics are broadly distributed in the plant 22 
kingdom and are the most abundant secondary metabolites found in plants. Various in vitro 23 
and in vivo evidence show that several (poly)phenol-rich foods are protective against chronic 24 
diseases, including cardiovascular disease, neurodegeneration, and cancer (Del Rio et al. 25 
2013). 26 
One of the principal topics concerning the beneficial effects of (poly)phenols is their bio-27 
availability and metabolic fate. Most of dietary phenolic compounds are subjected to 28 
extensive metabolism prior and after the absorption such that, with very few exceptions, only 29 
metabolites of the parent compounds enter the circulatory system (Del Rio et al. 2013). As a 30 
result, the gastrointestinal tract could be the location for the health benefits derived from a 31 
diet rich in (poly)phenols. Phenolic compounds might exert direct protective effects in the 32 
gastrointestinal tract, by scavenging reactive oxygen species (Halliwell et al. 2000). The 33 
inhibition of intestinal carcinogenesis by red wine (poly)phenols, grape seed extract and 34 
berries has been demonstrated in cell lines, animal model systems and humans (Dolara et al. 35 
2005; Kaur et al. 2006; Adhami et al. 2009). In addition, (poly)phenols are able to inhibit 36 
some intestinal digestive enzymes such as lipase and glucosidases, modulating nutrients 37 
bioavailability and resulting in a beneficial effect on obesity and blood glucose control 38 
(McDougall and Stewart 2005). 39 
The prevalence of type II diabetes is rising exponentially and particular non-insulin-40 
dependent diabetes mellitus is intimately associated to cardiovascular complications as a 41 
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consequence of post-prandial hyperglycemic condition (Nathanson and Nyström 2009). 42 
Inhibitors of intestinal α-glucosidase enzymes retard the rate of carbohydrate digestion, 43 
contributing to reduce post-prandial hyperglycemia (Krentz and Bailey 2005). The use of 44 
commercial α-glucosidase inhibitors (acarbose, miglitol and voglibose) is limited by their 45 
gastro-intestinal intolerability and high cost. One intriguing approach to control 46 
hyperglycemia could be its prevention by phytochemicals present in the diet. Several reports 47 
have been published in recent years showing that berry, red wine and green tea (poly)phenols 48 
are able to inhibit in vitro intestinal glucosidases, potentially suggesting their efficacy in an 49 
effective management of diabetes mellitus (Boath et al. 2012a; Kwon et al. 2008).  50 
Pomegranate (Punica granatum L.) is a rich source of phytochemicals, mainly anthocyanins, 51 
ellagitannins (punicalin, punicalagin, pedunculagin) and ellagic acid with antioxidant, anti-52 
cancer and cardiovascular protective activities (Medjakovic and Jungbauer 2013; Usta et al. 53 
2013). Pomegranate has also been studied for its anti-diabetic properties.  54 
Pomegranate juice supplementation significantly reduced post-prandial blood glucose but not 55 
triacylglycerols and cholesterol levels in streptozotocin-induced diabetic mice fed with a 56 
high-fat diet (Betanzos Cabrera et al. 2011). Indeed, Punica granatum flower extract was able 57 
to reduce post-prandial hyperglycemia in Zucker diabetic fatty rats (Li et al. 2005). 58 
A possible explanation for these observations is that pomegranate juice possesses α-59 
glucosidase or α-amylase inhibitors able to attenuate the post-prandial increase in glycemia. A 60 
reduction of α-glucosidase activity was observed in the saliva of healthy humans after the 61 
consumption of pomegranate extract during an intervention study (Di Silvestro et al. 2009).  62 
The present study tested a pomegranate (poly)phenol-rich extract for α-glucosidase and α-63 
amylase inhibitory activity to determine its potential mechanism of action as hypoglycemic 64 
agent. Pomegranate extract was subsequently fractionated with the aim to identify compounds 65 
that may influence the enzymatic activities. Finally, the inhibitory effect on carbohydrate 66 
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hydrolysis of pomegranate extract was tested against a real food system (potatoes) using an in 67 
vitro digestion model. 68 
69 




 Materials 72 
 73 
α-Glucosidase (EC 3.2.1.20) from rat intestinal acetone powder, porcine pancreatic α-amylase 74 
(EC 3.2. 1.1), bile salts (mixture of sodium cholate and sodium deoxycholate), pepsin from 75 
porcine gastric mucosa, pancreatin from porcine pancreas, potato starch,  p-nitrophenyl α-D-76 
glucoside (PNP-gluc), acarbose and Sephadex LH-20 were purchased from Sigma Chemical 77 
Co. (Milan, Italy). All the other chemicals for enzymatic reactions and digestion procedure 78 
were obtained from Sigma Chemical Co. (Milan, Italy). Formic acid, acetonitrile, ethanol and 79 
methanol for column chromatography, HPLC and LC-MS analysis were from Carlo Erba 80 
(Milan, Italy). Standard compounds for HPLC analysis were also supplied by Sigma 81 
Chemical Co. (Milan, Italy) except punicalin that was purified from pomegranate extract. 82 
Sephadex C-18 columns (quantity of sorbent 10000 mg) were supplied by Alltech (Deerfield, 83 
IL). Pomegranate juice (Azienda Montana Achillea; Paesana, Cn, Italy) was purchased from a 84 
local supermarket (Reggio Emilia, Italy) and was 100% pure pomegranate juice. 85 
 86 
Sample preparation and total (poly)phenol determination 87 
 88 
Pomegranate juice (poly)phenol-rich extract was obtained using C18 solid-phase extraction 89 
(Verzelloni et al. 2007). Columns were pre-conditioned with 60 mL of methanol and 90 
subsequently with 40 mL of 0.1% formic acid in water. The pomegranate juice was loaded 91 
(20 mL) and 60 mL of 0.1% formic acid was used to elute unbound materials (free sugars, 92 
organic acids and vitamin C). The bound materials, containing pomegranate (poly)phenols, 93 
were eluted with 60 ml of methanol. The solvent was removed by a rotary evaporator to near 94 
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dryness and then freeze-dried. The pomegranate extract was tested for its ability to inhibit the 95 
activity of α-glucosidase and α-amylase. 96 
Total (poly)phenols in pomegranate juice and extract were determined using the Folin-97 
Ciocalteau method (Singleton et al. 1999). The total phenolic content was expressed in 98 
mmol/L of ellagic acid equivalents, using ellagic acid as standard at concentrations ranging 99 
between 20 and 1000 mmols/L. The choice of the standard was carried out considering that 100 
ellagitannins (which are built up with ellagic acid units) are the most predominant  phenolic 101 
components present in pomegranate juice (Fischer et al. 2011). 102 
 103 
Amylase assay 104 
 105 
Amylase assay was carried out as reported by McDougall et al. (2005) using porcine 106 
pancreatic α-amylase and soluble potato starch as a substrate. The reaction was performed in 107 
20 mmol/L sodium phosphate buffer pH 6.9 containing 6.7 mmol/L NaCl. For the reaction, 108 
0.1 mL of 2 U/mL amylase solution (one unit of amylase is defined as the quantity of enzyme 109 
that releases 1.0 mg of maltose from starch in 3 minutes at pH 6.9 at 20°C) was mixed with 110 
0.9 mL of sodium posphate buffer or different concentrations of pomegranate extract 111 
dissolved in the sodium posphate buffer. After 10 min at 37°C, 1 mL of 1% starch solution 112 
(dissolved in the sodium posphate buffer) was added and the reaction mixture was incubated 113 
at 37°C for 30 min. The reaction was terminated by adding 1 mL of dinitrosalicylic acid 114 
solution and boiling for 15 min in a water bath. Enzyme activity was quantified by measuring 115 
the mg of maltose released from starch by reading at 540 nm. To calculate the IC50 value, the 116 
enzyme activity was determined in the presence of pomegranate extract with phenols 117 
concentrations ranging from 150 to 3000 μmol/L. The IC50 is defined as the concentration of 118 
phenolics required to inhibit 50% of the enzymatic activity. 119 
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 120 
 α-Glucosidase assay 121 
 122 
The enzyme α-glucosidase was extracted from rat intestinal acetone powder and assayed 123 
according to Oki et al. (1999). The rate of release of p-nitrophenol (PNP) from PNP-gluc was 124 
measured at 37 °C after incubation for 20 min in presence of 0.01 U/mL of rat intestinal α-125 
glucosidase (one unit of α-glucosidase is defined as the quantity of enzyme that releases 1.0 126 
μmol of PNP from PNP-gluc per minute at pH 6.8 at 37°C). For the reaction, 0.1 mL of 0.2 127 
U/mL of rat intestinal α-glucosidase was pre-incubated with 0.9 mL of buffer (potassium 128 
phosphate buffer 67 mmol/L, pH 6.8) or different concentration of pomegranate extract 129 
dissolved in buffer. After 10 min at 37°C, 1 mL of substrate solution (containing 1 mmol/L 130 
PNP-gluc and 0.2 mmol/L of glutathione dissolved in potassium phosphate buffer) was added 131 
and the reaction mixture was incubated at 37°C for 20 min. The reaction was terminated by 132 
adding 4 mL of 100 mmol/L sodium carbonate solution. Enzyme activity was quantified by 133 
measuring the μmol of PNP released from PNP-gluc by reading at 400 nm. To determine the 134 
IC50 value, the enzyme activity was determined in the presence of pomegranate extract with 135 
phenols concentrations ranging from 150 to 3000 μmol/L. The IC50 is defined as the 136 
concentration of phenolics required to inhibit 50% of the enzymatic activity. 137 
 138 
Pomegranate juice (poly)phenol-rich extract fractionation 139 
 140 
To identify compounds responsible for the inhibitory activity, pomegranate extract was 141 
fractionated using Sephadex LH-20 with the method adapted from the Tannin Handbook 142 
(available at www.users.muohio.edu/hagermae/tannin.pdf). Sorption to Sephadex LH-20 in 143 
aqueous ethanol and selective de-binding with aqueous acetone is an established method for 144 
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separating tannins from non-tannin phenolics). Briefly, after column preconditioning with 145 
80% ethanol, the pomegranate extract in 80% ethanol was applied to the column. The 146 
unbound material (anthocyanins and other monomeric phenolic compounds) was collected 147 
after washing with three volumes of 80% ethanol. The bound fraction (ellagitannins) was 148 
eluted with three volumes of 50% acetone. Both the fractions were evaporated by a rotary 149 
evaporator to near dryness and and then freeze-dried. All the fractions were subjected to LC-150 
ESI-MS/MS analysis and tested for their ability to inhibit the hydrolytic enzymes. 151 
 152 
LC-ESI-MS/MS analysis 153 
 154 
LC–MS/MS analysis were carried out according to Fischer et al. (2011) using an Agilent 155 
system 6310A Ion Trap LC-MSn (Agilent, Waldbronn, Germany) equipped with degasser, 156 
binary gradient pump, thermo-autosampler and column oven. The MS/MS system was ion 157 
trap mass spectrometer fitted with an ESI source. Data acquisition and processing were 158 
performed using DataAnalysis software. Negative ion (ellagitannins) mass spectra of the 159 
column eluate were recorded in the range of m/z 50–1300 at a scan speed of 13,000 m/z/s. 160 
The mobile phase, solvent A (1% formic acid) and solvent B (acetonitrile), was used under 161 
binary linear gradient conditions as follows: 5-15% B (10 min), 15-25% B (20 min), 25–50% 162 
B (3 min), 50% B isocratic (4 min); with a flow rate of 1 mL/min. 163 
For anthocyanins identification, positive ion mass spectra of the column eluate were recorded 164 
in the range of m/z 50–1300 at a scan speed of 13,000 m/z/s. The mobile phase consists of (A) 165 
formic acid 2% in HPLC water and (B) formic acid 2% in methanol HPLC grade. The 166 
following gradient was applied: 10–14% B (5 min), 14–23% B (11 min), 23–35% B (5 min), 167 
35–40% B (14 min), 40–100% B (3 min), 100% B isocratic (3 min), 100–10% B (3 min), 168 
10% B isocratic (4 min). The flow rate was 1 mL/min. 169 
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The nebuliser gas temperature was set at 400° C. Helium was used as collision gas at a 170 
pressure of 4x10-6 mbar. 171 
 172 
HPLC-DAD analysis 173 
 174 
Individual phenolic compounds were quantified using an HPLC system consisted of a Jasco 175 
HPLC system (Orlando FL, U.S.A.) equipped with a diode array detector, a reversed phase 176 
column Hamilton HxSil C18 (Hamilton, Reno, Nevada; 250mm x 4.6mm), a volumetric 177 
injector Rheodyne (Cotati, CA), and a temperature-controlled oven. 178 
For ellagitannins quantification, the monitored wavelength was 360 nm. Identification and 179 
quantification of punicalagins A and B, ellagic acid and punicalin in samples were performed 180 
using calibration curves of the respective standards compounds. For this reason, a stock 181 
solutions of standard compounds were diluted at different concentrations and the solutions 182 
were analysed.  183 
Anthocyanins were quantified at a wavelength of 520 nm as cyanidin-3-glucoside equivalents. 184 
The HPLC parameters were the same as reported in the previous section. 185 
 186 
Identification of α-glucosidase inhibitors 187 
  188 
The ellagitannins recognized by LC-MS/MS were tested for their α-glucosidase inhibitory 189 
activity. Ellagic acid and punicalagin (a mixture of A and B isomers)  were obtained from 190 
Sigma Chemical Co. (Milan, Italy) as pure compounds (95% of purity degree). Punicalin was 191 
purified from pomegranate juice following the procedure reported in Aviram et al. (2008). 192 
Purified compound was evaporated by a rotary evaporator to near dryness and then freeze-193 
dried. The purified compound was characterized by LC-ESI-MS/MS and the purity assayed 194 
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with HPLC-DAD (95% of purity degree as deduced from the ratio of the peak area of the 195 
isolated compounds and total peak area at 280 nm; see supplementary figure).  196 
For the calculation of IC50 values, α-glucosidase assay was carried out in the presence of 197 
variable amounts (from 10 to 500 μmol/L) of punicalin, punicalagin or ellagic acid.  198 
 199 
In vitro gastro-intestinal digestion 200 
 201 
The gastro-intestinal system was adapted from Tagliazucchi et al. (2012) with some 202 
modifications. Potatoes, selected as real starch-rich food, were weighed, peeled, and cooked 203 
whole in boiling water for 30 min. They were removed and cooled at ambient temperature 204 
(21°C) to be handled. Ten grams of cooked potatoes (corresponding to 1.71 g of starch) were 205 
homogenized in a laboratory blender for 1 min to simulate mastication in presence of 5 mL of 206 
simulated salivary fluid and 20 mL of different concentrations of pomegranate extract 207 
dissolved in a 0.1 M phosphate-buffer (pH 6.9). The artificial saliva consisted of a 0.1 M 208 
phosphate-buffer (pH 6.9) containing 1.336 mmol/L CaCl2, 0.174 mmol/L MgSO4, 12.8 209 
mmol/L KH2PO4, and 23.8 mmol/L NaHCO3, 2 g/L of food casein (known to be a proline-210 
rich protein), and 150 units/L α-amylase.  211 
In the control digestion, the pomegranate extract was omitted and the cooked potatoes (10g) 212 
were homogenized in presence of 5 mL of simulated salivary fluid and 20 mL of the 0.1 M 213 
phosphate-buffer (pH 6.9). 214 
After 10 minutes of incubation at 37°C in a shaking bath, the pH was adjusted to 2.5 (to 215 
simulate gastric pH) with concentrated HCl and after 2 g/L of NaCl and 315 U/mL of pepsin 216 
were added. The solution was incubated at 37°C in a shaking bath at 100 rpm for 2 h. At the 217 
end of the gastric digestion, the pH was brought to 7.5 with NaHCO3 (to simulate hepato-218 
pancreatic pH) before adding 0.8 g/L of pancreatin, 5 mg/mL of bile salts and 2 mL of rat 219 
   12 
 
intestinal solution containing 10 U of α-glucosidase. On the basis of the added pancreatin, the 220 
amount of digestive enzymes in the intestinal fluid was 80 U/mL of α-amylase, 240 U/mL of 221 
proteases and 384 U/mL of lipase. The solution was then incubated at 37°C in a shaking bath 222 
at 100 rpm for a further 2 h.  223 
The amount of glucose released at the end of the digestion was quantified using a hexokinase, 224 
glucose-6-phosphate dehydrogenase, phospho-glucose isomerase method (Kunst et al. 1984). 225 
The ellagitannins were quantified by HPLC-DAD as reported in the previous section. 226 
 227 
Statistical analysis  228 
 229 
All data are presented as mean ± SD for three replicates for each prepared sample. The 230 
Student’s t-test and ANOVA with Tukey post-hoc test was performed using Graph Pad Prism 231 
(GraphPad Software, San Diego, CA). The differences were considered significant with P 232 
<0.05. The IC50 values were determined using nonlinear regression analysis and fitting the 233 
data with the log(inhibitor) vs. response model (Graph Pad Prism). 234 
235 
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Results  236 
 237 
The pomegranate juice contained 6.82 ± 0.75 mmol of ellagic acid equivalent (EAE)/L of 238 
phenolic compounds. The percentage of the recovery in the C18 bound fraction, 239 
corresponding to the pomegranate extract, was 86% of total (poly)phenols (5.87 ± 0.26 mmol 240 
of ellagic acid equivalent (EAE)/L). 241 
Pomegranate extract was an effective inhibitor of rat intestinal α-glucosidase with an IC50 242 
value of 922.8 ± 1.2 μmol of EAE equivalent/L (Figure 1). Acarbose inhibited α-glucosidase 243 
in a dose-dependent manner giving an IC50 value of 69.7 μmol/L. 244 
On the contrary, pomegranate extract was a weak inhibitor of α-amylase. At the highest tested 245 
concentration, corresponding to a final concentration of pomegranate (poly)phenols in the 246 
assay of 3000 μmol of EAE equivalent/L, the α-amylase activity was inhibited by 42%. These 247 
results showed that pomegranate extract contained potent inhibitors of rat intestinal α-248 
glucosidase. 249 
The pomegranate extract was fractionated in two different fractions with Sephadex LH-20. 250 
The phenolic compounds in the two Sephadex LH-20 fractions were characterised by LC-251 
ESI-MS/MS analysis and the individual compounds quantified by HPLC-DAD analysis. The 252 
LH-20 unbound material was pink and contained mainly anthocyanins (Figure 2) as 253 
delphinidin 3,5-diglucoside (19.6 ± 0.4 µmol/L), cyanidin 3,5-diglucoside  (57.5 ± 1.2 254 
µmol/L), pelargonidin 3,5-diglucoside (11.6 ± 0.2 µmol/L), delphinidin 3-glucoside (11.1 ± 255 
0.2 µmol/L) and cyanidin 3-glucoside (12.8 ± 0.4 µmol/L), low levels of ellagitannins and 256 
unidentified flavonols. Instead the LH-20 bound material was brown and contained the 257 
majority of ellagitannins (Figure 3).  258 
Enzymatic analysis showed that only the LH-20 bound fraction caused inhibition of α-259 
glucosidase, whereas the LH-20 unbound fraction did not show any inhibitory activity, even 260 
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at the highest tested concentrations. It is interesting to note that also the majority of the α-261 
amylase inhibitory activity was recovered in the LH-20 bound fraction, with only a marginal 262 
activity found in the LH-20 unbound material. 263 
The retention times, concentration (µmol/L) and mass spectral characteristics of the 264 
ellagitannins are specified in Table 1. 265 
Punicalin is the major ellagitannins (peak 6; figure 3A) found in the pomegranate extract; this 266 
compound present an [M-H]- ion at m/z 781 and fragments at m/z 601 and 602 for the loss of 267 
gallagic acid moiety. 268 
Punicalagin showed an [M-H]- ion at m/z 1083 but it can be also detected as doubly charged 269 
ion species at m/z 541. The fragment at m/z 601 in MS/MS experiment showed the loss of a 270 
gallagic acid moiety and a fragment with m/z 781 was observed equivalent to the [M-H]- ion 271 
of punicalin. The presence of the two isomers A and B (peaks 7 and 8; figure 3A) was 272 
confirmed by the different retention times of the commercial standard isomers. 273 
The compound eluting at 15.0 min exhibited an [M-H]- ion at m/z 783. The loss of water 274 
moiety and ellagic acid (m/z 301) in MS/MS experiment produced fragments at m/z 765 and 275 
m/z 481, respectively. Based on this fragmentation pathway and a previous study (Okuda et 276 
al. 1983) this compound was identified as bis-HHDP-hexoside (pedunculagin A; peak 9; 277 
figure 3A). 278 
The compound present in the peak 10 (figure 3A) eluted at 18.4 min and exhibited an [M-H]- 279 
ion at m/z 951. In MS/MS experiment produced fragments at m/z 933 and 934. Furthermore, 280 
fragments at m/z 915 were obtained from the loss of water moiety from principal fragment 281 
(m/z 933) and the ion at m/z 897 by dehydration. This compound was tentatively identified as 282 
granatin B based on the fragmentation pattern reported in previous study (Fischer et al. 2001). 283 
The compound which eluted at 19.7 min with fragment at m/z 463 was identified as ellagic 284 
acid-hexoside (peak 11; figure 3A). This compound produced fragments at m/z 300, 301, 302 285 
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in MS/MS experiment, typical m/z fragments of ellagic acid. Ellagic acid-hexoside has 286 
previously reported in pomegranate juice and arils (Fischer et al. 2001). 287 
The last identified compound was ellagic acid (peak 12; figure 3A). The aglycone moiety 288 
(m/z 301) produced characteristic fragments at m/z 229, 201 and 185 in MS/MS experiment. 289 
Ellagitannins and ellagic acid were therefore identified as the α-glucosidase inhibitors present 290 
in the pomegranate extract. The IC50 values of the individual ellagitannins, revealed that 291 
punicalagin was the most effective inhibitor of α-glucosidase (IC50 of 140.2 ± 1.1 μmol/L) 292 
followed by punicalin and ellagic acid (IC50 of 191.4 ± 1.3 μmol/L and 380.9 ± 3.5 μmol/L, 293 
respectively).  294 
To gain more information about the role of each identified ellagitannins in the α-glucosidase 295 
activity inhibition, their contribution ratio was calculated by dividing the power of inhibitory 296 
activity of each identified compound (calculated by dividing the amount of each single 297 
compound in the extract in μmol/L by its IC50 value in μmol/L) with that of the pomegranate 298 
extract (calculated by dividing the total (poly)phenolic content of the extract in μmol/L by its 299 
IC50 value in μmol/L) (Toshima et al., 2010). The obtained value was than multiplied by 100 300 
to estimate the contribution ratio as %. For example, the contribution ratio of punicalagin was 301 
calculated as follows: (232.2/140.2)*100/(5870/922.8) = 26%. The same calculation for 302 
punicalin and ellagic acid provides contribution ratio values of 54 and 3%, respectively. The 303 
data reported clearly indicated that the α-glucosidase inhibitory activity of pomegranate 304 
extract was due to punicalin and punicalagin with a minor contribution of ellagic acid. 305 
 306 
Kinetic analysis and mechanism of inhibition 307 
 308 
In the original assay, the pomegranate extract was mixed with α-glucosidase and buffer, pre-309 
incubated for 10 min and the reaction started by the addition of the substrate. If the order of 310 
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addition of components was changed and the reaction started by the addition of the enzyme 311 
rather than the substrate, then the pomegranate extract was less effective (Figure 4A). The 312 
same effect was observed when different concentrations of ellagic acid were pre-incubated for 313 
0, 5, 10, 30 or 60 min with α-glucosidase (Figure 4B). This results suggested that 314 
pomegranate ellagitannins interacted directly with the α-glucosidase. 315 
The ellagitannin punicalagin as well as the pomegranate extract were selected as test 316 
inhibitors for the kinetic analysis. All the tested samples reduced the Vmax and increased KM 317 
of α-glucosidase (Table 2). These results suggested a mixed-type inhibition with respect to 318 
substrate concentration. 319 
 320 
Effect of pomegranate extract on potato starch hydrolysis during in vitro gastro-intestinal 321 
digestion 322 
 323 
The ability of the pomegranate extract to inhibit starch hydrolysis was assessed using a real 324 
food during simulated gastro-intestinal conditions. Cooked potatoes was firstly subjected to 325 
mastication, in presence of simulated salivary fluid which contained 150 units/L of α-amylase. 326 
After 10 minutes, the bolus was subjected to consecutive gastric (2 h) and intestinal (2 h) 327 
digestion, in presence of 80 units/mL of α-amylase and 370 units/L of α-glucosidase.  328 
At the end of the gastro-intestinal digestion, in absence of the pomegranate extract, the 329 
amount of released glucose was 199.5 ± 2.12 mg/g of potato starch. The addition of the 330 
pomegranate extract in the digestive system produced a decrease in the amount of released 331 
glucose at the end of the gastro-intestinal digestion of 18 and 44% when the digestion was 332 
carried out with 2.35 or 4.7 mmol/L of total (poly)phenols, respectively. Control experiments 333 
carried out without enzymes showed that there was no hydrolysis of potato starch. 334 
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The behaviour of the ellagitannins during simulated gastro-intestinal digestion of potatoes 335 
was followed with HPLC-DAD. The results are detailed in Table 3. The concentration of the 336 
ellagitannins punicalin and punicalagin decreased by 22.6 and 30.9% after mastication and by 337 
36.8 and 61.6% after pancreatic digestion, respectively. The amount of ellagic acid increases 338 
to 142.8 and 234.2% after mastication and pancreatic digestion, respectively.  339 
340 




This is the first report showing that pomegranate juice (poly)phenolic extract is a potent 343 
inhibitor of in vitro carbohydrate digestion. Pomegranate extract strongly inhibited the rat 344 
intestinal α-glucosidase activity in vitro. 345 
The ability of the pomegranate (poly)phenolic-rich extract to inhibit the starch hydrolysis was 346 
also demonstrated using an in vitro digestion system, mimicking the physiological gastro-347 
intestinal condition, and potatoes as food rich in starch.  348 
A variety of food (poly)phenolic extracts have been shown to inhibit α-amylase and α-349 
glucosidase activities in vitro. Rat intestinal α-glucosidase inhibitory activity of pomegranate 350 
extract (IC50 value of  278 μg/mL) is lower than that of acarbose (IC50 of  45 μg/mL ), 351 
anthocyanins-rich berry extracts (such as blueberry, blackcurrant, rowanberry, and 352 
strawberry; IC50 values from 18 to 42 μg/mL), and black tea (IC50 of  64 μg/mL) (McDougall 353 
et al., 2005, Koh et al. 2010). However, the in vitro inhibitory activity of pomegranate extract 354 
was similar to that of green tea (IC50 value of  297 μg/mL) which has been found to be 355 
effective in reducing postprandial blood glucose level in vivo (Tang et al. 2013).  356 
The inhibitory activity against both the enzymes was assigned to ellagitannins, especially 357 
punicalin and punicalagin. The comparison of the IC50 values against rat intestinal α-358 
glucosidase of punicalagin and punicalin (140.2 and 191.4 μmol/L, respectively) with that of 359 
other (poly)phenols revealed that these compounds are effective as theaflavin digallate (IC50 360 
of  165 μmol/L, Koh et al. 2010) and diacilated anthocyanins (IC50 of  200 μmol/L, Matsui et 361 
al. 2002). Pomegranate ellagitannins are more effective than green tea catechins (Koh et al. 362 
2010), and flavonols (Tadera et al. 2006). Pomegranate ellagitannins are less effective than 363 
acarbose (IC50 of 69.7 μmol/L). 364 
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Punicalagin, despite its lower IC50 value against rat intestinal α-glucosidase, was not the most 365 
important contributor to the inhibitory activity (26% of contribution). In contrast, punicalin 366 
was estimated to be the main contributor to pomegranate extract α-glucosidase inhibition 367 
(54% of contribution) owing to its higher content in the extract. The total contribution ratio of 368 
all identified ellagitannins in this study was 83%, suggesting that some unidentified 369 
compounds with α-glucosidase inhibitory activity can be present in the pomegranate extract or 370 
that synergic effects should be considered. 371 
Kinetic analysis suggested that pomegranate extract, and ellagitannins inhibited α-glucosidase 372 
activity in a mixed mode. The pre-incubation and the order of addition experiments indicate 373 
that ellagitannins influence α-glucosidase activity via their ability to bind proteins (Wang et 374 
al. 2013). The non-specific binding of ellagitannins with α-glucosidase may alter the structure 375 
of the enzyme by reducing the velocity of the catalysis and the accessibility to the active site 376 
of the substrate. 377 
Most of the studies previously published on the inhibitory activity of (poly)phenols or 378 
(poly)phenols-rich extract against α-amylase and α-glucosidase were carried out using 379 
enzymatic assay that did not represent the physiological conditions of the gastro-intestinal 380 
tract. One of the most important criticisms in employing the enzymatic assay is the use of 381 
starch solution or synthetic substrate solution instead of real food. The importance of utilizing 382 
real food lies in the presence of additional molecules (such as proteins, lipids and fibers), 383 
other than starch, that may impede the effect of (poly)phenols on the enzymes. An additional 384 
criticism is related to the fact that phenolic compounds are somewhat unstable under real or 385 
simulated gastro-intestinal conditions. For example it has been shown that anthocyanins are 386 
degraded in the pancreatic media (Liu et al. 2014) whereas ellagitannins may undergo partial 387 
breakdown in the gastro-intestinal tract (Larrosa et al. 2010). To overcome this point, we 388 
tested the ability of pomegranate (poly)phenols to inhibit the carbohydrate hydrolysis during 389 
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simulated digestion of potatoes. Results show that the pomegranate extract is able to inhibit in 390 
a concentration dependent manner potato starch digestion under in vitro gastro-intestinal 391 
conditions. Despite all the limitations of the model system (static model, glucosidase not 392 
bound to the enterocyte membrane), our results allow us to infer that pomegranate 393 
(poly)phenols may be effective inhibitors of starch digestion also in vivo by inhibiting the 394 
activity of α-glucosidase. Our results show that a portion of pomegranate juice (200 ml) is 395 
able to inhibit the starch hydrolysis by about 50% during the digestion of a portion (100 g) of 396 
potatoes. As already observed, ellagitannins are not stable under gastro-intestinal condition 397 
(Larrosa et al. 2010). We found a decrease in the concentration of the ellagitannins punicalin 398 
and punicalagin by 22.6 and 30.9% after mastication. These decreases may be due to the 399 
irreversible binding of ellagitannins to salivary or potato proteins (Wang et al., 2013) or to the 400 
hydrolysis of punicalin and punicalagin (Cerdá et al. 2003). In the proposed gastro-intestinal 401 
hydrolysis pathway, punicalagin breakdown releases equimolar concentrations of ellagic acid 402 
and punicalin which is further hydrolyzed to give equimolar concentrations of gallagic acid 403 
and glucose (Cerdá et al. 2003). 404 
The loss of punicalagins during the salivary phase of the digestion was not accompanied by 405 
the appearance of substantive amounts of ellagic acid; the ellagic acid concentration, in fact, 406 
increased after mastication of 31.8 μmol/L, whereas the concentration of punicalagins 407 
decreased by about 71.9 μmol/L. This is indicative of the fact that part of the ellagitannins 408 
bind potatoes or salivary proteins during the oral phase of the digestion. The concentration of 409 
punicalagins remained constant during the gastric phase whereas the intestinal phase caused a 410 
further decrease in their concentration. The loss of punicalagins in the intestinal media is 411 
totally explained by its hydrolysis to ellagic acid. The punicalagin concentration decreased 412 
after intestinal hydrolysis of 71.3 μmol/L which is accompanied by the appearance of 69.3 413 
μmol/L of ellagic acid. It is interesting to note the data of ellagic acid concentration after the 414 
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gastric phase. The concentration of ellagic acid dropped to 5 μmol/L at the end of the gastric 415 
digestion because of its poor solubility in acidic media (Larrosa et al. 2010) and, after the 416 
passage in the alkaline intestinal fluid, it returned into the solution. Surprisingly, punicalin 417 
concentration did not change further during simulated intestinal digestion respect to the 418 
gastric phase. Punicalin was not stable under intestinal conditions but its loss was 419 
compensated by the hydrolysis of punicalagin forming punicalin and ellagic acid. 420 
Thus, the increase of ellagic acid that was observed in the last phase of the intestinal digestion 421 
is due mostly to the instability of punicalagin in the intestinal environment, with release of 422 
ellagic acid moieties and punicalin. 423 
Despite the binding between ellagitannins and proteins and their hydrolysis in the gastro-424 
intestinal media, the pomegranate extract maintained its ability to inhibit starch digestion. 425 
This means that hydrolysis of ellagitannins releases compounds with inhibitory activity. For 426 
example punicalin and ellagic acid, that are released from punicalagin, are still able to inhibit 427 
α-glucosidase and therefore starch hydrolysis during the digestion of potatoes. 428 
There is some in vivo and in vitro evidence showing that pomegranate juice may be helpful 429 
for type II diabetic subjects. Firstly, there are studies reporting the hypoglycemic activity of 430 
pomegranate juice in rats (Betanzos-Cabrera et al., 2011) and in diabetic patients (Rock et al. 431 
2008; Rosenblat et al. 2006). Till now the mechanism has not been elucidated, but our data 432 
strongly suggest that the hypoglycemic activity of pomegranate juice is due to the ability of 433 
ellagitannins to inhibit starch hydrolysis. Some in vivo studies highlighted the protective 434 
effect of pomegranate juice on some oxidative complications in diabetic patients. Rosenblat et 435 
al. (2006) demonstrated that the consumption of pomegranate juice by diabetic patients 436 
significantly decreased serum oxidative stress and the extent of oxidized LDL uptake by 437 
macrophages. This effect was mediated by PPARγ activation (Shiner et al. 2007). Moreover, 438 
the same research group showed that pomegranate juice consumption by diabetic patients 439 
   22 
 
could lead to a delay in the atherosclerosis development by increasing paraoxonase 1 440 
stabilization and association with HDL and stimulating its catalytic activity (Betanzos-441 
Cabrera et al. 2011; Fuhrman et al. 2010). This effect is likely mediated by ellagitannins 442 
metabolites such as ellagic acid and urolithins (González-Barrio et al. 2010; Park et al. 2011). 443 
Pomegranate ellagitannins, in fact, are not absorbed and bioavailable in the human body but 444 
are hydrolyzed during the gastro-intestinal digestion releasing ellagic acid that is afterwards 445 
bio-transformed in urolithins by the action of colonic microbiota (González-Barrio et al. 446 
2010). Urolithins are well absorbed in the human colon, mainly urolithin-A or urolithin-B 447 
and/or iso-urolithin-A according to urolithin phenotype in each person due to the different 448 
microbiota communities (Tomás-Barberán et al. 2014), and although they display low 449 
antioxidant activity are able in vitro to counteract two key features of diabetic complications, 450 
i.e. protein glycation and neurodegeneration (Verzelloni et al. 2011). Thus, pomegranate juice 451 
(poly)phenols and metabolites could act at different level in attenuates type II diabetic 452 
complications. They may act at gastro-intestinal level, where the ellagitannins punicalin, 453 
punicalagin and ellagic acid inhibit starch hydrolysis, resulting in a hypoglycaemic effect. At 454 
systemic level, the ellagitannins metabolites (ellagic acid, urolithins and their phase II 455 
metabolites) may counteract protein glycation and exert anti-atherosclerotic effects, thus 456 
reducing some diabetic complications. 457 
458 
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5. Conclusions 459 
 460 
We were able to identify the ellagitannins punicalin and punicalagin as α-glucosidase 461 
inhibitors in pomegranate juice. Ellagitannins retained their inhibitory activity in a in vitro 462 
model of the digestive system and using cooked potatoes as a source of starch. 463 
In conclusion, our data together with literature data argue with the hypothesis that 464 
pomegranate juice can be considered as a rational complementary therapeutic agent to 465 
ameliorate postprandial hyperglycaemia linked to type II diabetes and hyperglycaemia-466 
induced vascular complications. 467 
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Figure captions  
 
Figure 1. Dose-dependent inhibition of rat intestinal α-glucosidase activity by pomegranate 
(poly)phenol-rich extract. The inhibitory activity of the pomegranate extract was measured at 
concentrations of 150, 300, 400, 600, 1000, 1500, 2000, and 3000 μmol/L. Values represent 
means of triplicate measurements. Data were analysed with nonlinear regression fit using the 
log(inhibitor) vs. response model (R2 = 0.975). Data are means ± SD (n = 3). 
Figure 2. HPLC chromatograms of pomegranate extract anthocyanins (A) and ellagitannins 
(B) in LH-20 unbound fraction. The monitored wavelength was 520 nm for the detection of 
anthocyanins and 360 nm for the detection of ellagitannins. Peak numbers as follows: (1) 
delphinidin 3,5-diglucoside, (2) cyanidin 3,5-diglucoside, (3) pelargonidin 3,5-diglucoside, 
(4) delphinidin 3-glucoside, (5) cyanidin 3-glucoside, (6) punicalin, (7) punicalagin A, (8) 
punicalagin B, (9) pedunculagin A, (10) granatin B, (11) ellagic acid-hex and (12) ellagic 
acid. 
Figure 3. HPLC chromatograms of pomegranate extract ellagitannins (A) and anthocyanins 
(B) in LH-20 bound fraction. The monitored wavelength was 360 nm for the detection of 
ellagitannins and 520 nm for the detection of anthocyanins. Peak numbers as follows: (6) 
punicalin, (7) punicalagin A, (8) punicalagin B, (9) pedunculagin A, (10) granatin B, (11) 
ellagic acid-hex, (12) ellagic acid and (2) cyanidin 3,5-diglucoside.  
Figure 4. (A) Effect of changing the order of addition of components on α-glucosidase 
inhibition by pomegranate extract. In the original assay, the pomegranate extract was mixed 
with the α-glucosidase and buffer, pre-incubated for 10 min at 37°C and the reaction started 
by the addition of the substrate. In the revised assay, the pomegranate extract was mixed with 
the substrate, incubated for 10 min at 37°C and than the reaction was initiated by the addition 
of the enzyme. The final concentration of pomegranate extract (poly)phenols in the assay was 
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2 mmol/L. Data are means ± SD (n = 3). (B) Effect of pre-incubation time and ellagic acid 
concentration on the α-glucosidase inhibitory activity of ellagic acid. Ellagic acid 
was pre-incubated for 0, 5, 10, 30, and 60 min with α-glucosidase before the addition of the 
substrate. Tested ellagic acid concentrations were:( ) 75 μmol/L, (□) 150 μmol/L, (■) 300 
μmol/L and (■) 600 μmol/L. * Indicate P < 0.05 respect to the previous time. Data are means 
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Data are means ± SD (n = 3). 
 




      
6 7.8 Punicalin   652.1 ± 40.5 781 MS2 [781]: 601, 602, 721 
7 11.3 Punicalagin A    85.6 ± 3.2    1083, 541 MS2 [1083]: 601, 602, 781 
8 13.2 Punicalagin B  146.6 ± 7.7 1083, 541 MS2 [1083]: 601, 602, 781 
9 15.0 Pedunculagin A     40.4 ± 1.0 783 MS2 [783]: 481, 301, 298, 721 
10 18.4 Granatin B     19.5 ± 0.3 951 MS2 [951]: 933, 934, 915, 897 
11 19.7 Ellagic acid-hex     31.8 ± 0.3 463 MS2 [463]: 300, 301, 302 
12 26.2 Ellagic acid     74.5 ± 3.6 301 MS2 [301]: 185, 201, 229 
      
  Total ellagitannins 1050.5 ± 56.6   
Table 2  
Effects of punicalagin and pomegranate polyphenol-rich extract on Vmax and KM values of α-
glucosidase. 
 
Vmax is reported as μmol of p-nitrophenol per min at pH 6.8 at 37°C whereas KM is expressed as mmol/L of p-
nitrophenyl α-D-glucoside. 








 Control Pomegranate polyphenol-rich extract (μmol/L) Punicalagins (μmol/L) 
 
 150 300 750 35 70 140 
Vmax 0.050 ± 0.002a 0.047± 0.004a 0.045± 0.004a 0.035± 0.005b 0.036 ± 0.003b 0.033 ± 0.002b 0.030 ± 0.004c 
KM 0.46 ± 0.02a 0.49 ± 0.02a 0.75 ± 0.03b 1.03 ± 0.05c 0.43 ± 0.02a 0.55 ± 0.01d 0.66 ± 0.02e 
Inhibition type / Mixed mixed 
Ki (μmol/L) / 483.80 77.16 
Table 3.  
Concentration (μmol/L) of ellagitannins in pomegranate polyphenol-rich extract subjected to in 










(before digestion) Post-masticated Post-gastric Post-pancreatic 
Punicalin 652.1 ± 40.5 504.5 ± 60.7* 408.5 ± 40.1 412.3 ± 40.0 
Punicalagins  232.2 ± 10.9 160.6 ± 10.1* 147.8 ± 7.6 89.3 ± 10.0* 
Ellagic acid 74.5 ± 3.6 106.6 ± 8.6* 5.0 ± 0.3* 175.9 ± 17.6* 
